AXGNMEDIUM SIGNALFINANCIAL10-K

AXGN showed solid revenue growth of 20% but experienced a substantial deterioration in net losses and a sharp decline in operating cash flow generation.

The significant widening of net losses despite revenue growth suggests margin compression or increased operational costs that merit investor attention. The dramatic decline in operating cash flow from $4.5M to just $812K raises questions about the company's cash conversion efficiency and working capital management.

Comparing 2026-02-24 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

AXGN delivered solid top-line growth with revenue increasing 20% to $225.2M, while strengthening its balance sheet position with higher cash reserves ($35.5M vs $27.6M) and reduced current liabilities. However, profitability deteriorated meaningfully with net losses substantially widening, and operating cash flow generation declined sharply to just $812K from $4.5M in the prior year. The company increased R&D investment by 18% and built up inventory levels, suggesting continued investment in growth despite near-term profitability challenges.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-82.1%
$4.5M$812K

Operating cash flow fell 82.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-57.6%
-$10.0M-$15.7M

Net income declined 57.6% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+29%
$27.6M$35.5M

Cash grew 29% — improving liquidity position supports investment and shareholder returns.

Inventory
Balance Sheet
+27.7%
$33.2M$42.4M

Inventory built 27.7% — monitor whether demand supports this build or if write-downs may follow.

Stockholders Equity
Balance Sheet
+24%
$103.9M$128.8M

Equity base grew 24% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-23%
$30.6M$23.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
+21.4%
$99.2M$120.4M

Current assets grew 21.4% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+20.8%
$3.1M$3.7M

Capex increased 20.8% — ongoing investment in capacity or infrastructure for future growth.

Revenue
P&L
+20.2%
$187.3M$225.2M

Revenue growing 20.2% — solid top-line momentum, watch margins for quality of growth.

R&D Expense
P&L
+18.4%
$27.8M$32.9M

R&D investment increased 18.4% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-26
ADDED
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 99 Item 9A.
FORWARD-LOOKING STATEMENTS From time to time, in reports filed with the U.S.
MARKET, INDUSTRY AND OTHER DATA This Annual Report on Form 10-K contains estimates, projections, and other information concerning our industry, and our business, including data regarding the estimated size of those markets.
Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources.
+7 more — sign up free →
REMOVED
Changes in and Disagreements w ith Accountants on Accounting and Financial Disclosure 100 Item 9A.
Form 10-K Summary 112 Signatures 113 P3 Table of Conten t FORWARD-LOOKING STATEMENTS From time to time, in reports filed with the U.S.
Our platform for peripheral nerve repair features a comprehensive portfolio of products, including: Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site.
Axoguard Nerve Connector , a porcine (pig) submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed peripheral nerves.
Axoguard Nerve Protector , a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →